Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (734)	6/4/2007 6:28:54 PM
From: Jibacoa	Respond to of 802

Some other comments.<g> DOW JONES NEWSWIRES. Introgen Therapeutics Inc. (INGN) said Monday that updated Phase II data shows a "significant correlation" between abnormal p53, tumor responses and increased survival following Advexin therapy in patients with recurrent squamous cell carcinoma of the head and neck. "These findings indicate important relationships between increased tumor responses and survival and the predictive abnormal p53 biomarker that is the target of Advexin treatment," said John Nemunaitis, medical director of the Mary Crowley Medical Research Center, in a statement. "We now have the ability to match patients with a treatment that may improve their survival, and if borne out in the ongoing Phase III clinical trials now undergoing analyses, could fulfill the promise of molecularly targeted cancer therapies." The data were presented at the annual meeting of the American Society of Clinical Oncology in Chicago. Snip. Again, no mention was made about trying to match survival with left handed patients.<g> Bernard